DoD Arthritis Research, Clinical Research Award
ID: 356099Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Arthritis Clinical Research Award (ATRP CRA) to support innovative clinical research aimed at improving outcomes for individuals affected by various types of arthritis. This grant program encourages proposals that address disease-specific factors and interventions, with a focus on military relevance and the potential for significant clinical impact, particularly for Service Members, Veterans, and their families. With an estimated total program funding of $6 million, the program anticipates awarding approximately three grants, including one for a clinical trial option, with applications due by October 30, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Defense's FY24 Arthritis Clinical Research Award aims to fund innovative, high-impact research focused on mitigating the effects of arthritis on service members and the general population. With a total budget of $10 million, the program encourages applications that address specific focus areas, including prevention, diagnosis, and intervention strategies for various types of arthritis. Eligible applicants can include academic institutions, non-profit organizations, and military personnel, with a pre-application deadline of October 16, 2024, and a full application deadline of October 30, 2024. Research proposals should demonstrate military relevance, potential clinical impact, and an intention to transition findings into practical applications. The award supports clinical trials with a maximum budget of up to $3 million and requires preliminary data. Applications must include detailed research strategies, recruitment plans, and a clear path to implementing findings post-award. The selection process involves peer review based on scientific merit and programmatic relevance, ultimately aimed at enhancing arthritis care and improving health outcomes for affected individuals.
    Similar Opportunities
    Alzheimer’s Research Program Transforming Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Research Award to support innovative research aimed at reducing the risk of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages diverse applicants, including for-profit, non-profit, and academic institutions, and emphasizes the necessity of community collaboration, particularly for clinical research projects. With an estimated total program funding of $4 million, the program anticipates awarding approximately four grants, each providing up to $1 million over a maximum of three years. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer’s Research Program Transforming Care Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Care Award to support innovative clinical research aimed at improving care for individuals with Alzheimer's disease and related dementias (AD/ADRD). This funding opportunity encourages community collaboration and requires projects to focus on interventions that enhance the quality of life for both patients and their caregivers. Approximately $5.2 million is available to fund around three awards, with pre-applications due by June 12, 2025, and full applications due by August 29, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity for the Duchenne Muscular Dystrophy Research Program's Clinical/Translational Research Award (CTRA) for fiscal year 2025. This funding initiative aims to support advanced translational research that accelerates promising ideas in Duchenne muscular dystrophy (DMD) into clinical applications, particularly focusing on therapies effective across all age groups, including infants and nonambulatory individuals. With an estimated total program funding of approximately $8.56 million, the program anticipates awarding around five grants, encouraging collaborations with early-career investigators and requiring applications to include preliminary data relevant to DMD. Interested applicants should note that a pre-application is due by July 25, 2025, with full applications due by August 8, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Medical Research Program, Technology/Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award (TTDA) to support the translation of promising preclinical findings into clinical applications for military personnel, veterans, and their families. This grant aims to facilitate the development of products that address military-related health challenges, including prevention, detection, diagnosis, treatment, or quality of life improvements, with a focus on innovative approaches in areas such as autoimmune disorders and infectious diseases. With an estimated total program funding of approximately $41.25 million available for up to 11 awards, applicants must submit a two-step application process, including a pre-application and a full application, by the closing date of July 21, 2025. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Military Burn, Patient-Centered Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Military Burn Research Program's Patient-Centered Research Award (PCRA) to enhance clinical practices and interventions for burn victims in combat conditions. This grant opportunity, with an estimated total funding of $3.4 million, specifically supports clinical research involving human subjects, excluding preclinical studies, and aims to bridge the gap between research and practical application in austere environments. Proposals should focus on improving acute burn care practices, developing methods to prevent and treat cold injuries, and managing complications such as fluid resuscitation and inhalation injuries, with a strong emphasis on military health relevance and potential impact. Interested applicants must submit pre-applications by June 23, 2025, and full applications by September 8, 2025, with funding announcements expected by September 30, 2026. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer’s Research Program Transforming Diagnosis Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Diagnosis Award to support innovative research aimed at enhancing the diagnosis and prognosis of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages community collaboration and requires the submission of preliminary data, with a focus on addressing barriers to effective dementia diagnosis. With an estimated total program funding of $3.2 million, the program anticipates awarding two grants, with funding caps set at $1.5 million for single Principal Investigator (PI) proposals and $1.7 million for those utilizing the Career Initiation or Transition Partnership Option. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Pilot Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award to support clinical trials aimed at improving the treatment and management of Amyotrophic Lateral Sclerosis (ALS). Applicants are required to focus on either biomarker-driven interventions or enhancements in clinical care, with an emphasis on incorporating community collaboration to optimize research impact. This funding opportunity allocates approximately $6.6 million to support around two pilot clinical trial applications, with a direct cost cap of $2 million for each project. Interested parties must submit a pre-application by June 6, 2025, followed by a full application due on August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Rare Cancers, Idea Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Rare Cancers Research Program (RCRP) Idea Development Award for fiscal year 2025. This grant aims to support innovative research that explores new ideas and develops impactful strategies in the area of rare cancers, which are defined as those affecting six or fewer individuals per 100,000 annually in the U.S. Eligible applicants include various organizations, and the program encourages interdisciplinary collaboration among military, academic, and industry sectors to enhance health outcomes for military Service Members, Veterans, and the broader public. The total estimated program funding is $6,860,000, with a funding limit of $490,000 per application. Key deadlines include a pre-application due by July 1, 2025, and a full application by October 6, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Rare Cancers, Resource and Community Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Rare Cancers Research Program Resource and Community Development Award, with an estimated total funding of $5.6 million aimed at enhancing research resources and clinical data related to rare cancers. This grant seeks to address critical gaps in rare cancer research, including the lack of resources, communication strategies, and data-sharing infrastructure, while emphasizing the integration of patient advocates throughout the project lifecycle. Eligible applicants include both domestic and foreign non-profit and for-profit organizations, with applications due by October 6, 2025, following a pre-application deadline of July 1, 2025. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) to support innovative research aimed at developing therapies for Amyotrophic Lateral Sclerosis (ALS). This grant program seeks applications that demonstrate proof-of-concept efficacy in preclinical models of ALS, with a focus on empirical therapeutic studies and the development of mechanism-specific biomarkers to enhance trial design and patient selection. With an estimated total funding of approximately $9.8 million, the program anticipates awarding about four grants, each capped at $1.5 million for a maximum duration of three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.